Gain Therapeutics, Inc.·4

Mar 28, 9:00 PM ET

Alder Matthias 4

4 · Gain Therapeutics, Inc. · Filed Mar 28, 2024

Insider Transaction Report

Form 4
Period: 2024-03-26
Alder Matthias
CHIEF OPERATING OFFICER
Transactions
  • Exercise/Conversion

    Common Stock

    2024-03-26+18,75025,763 total
  • Exercise/Conversion

    Common Stock

    2024-03-26+82526,588 total
  • Exercise/Conversion

    Common Stock

    2024-03-26+63727,225 total
  • Tax Payment

    Common Stock

    2024-03-26$4.06/sh6,085$24,70521,140 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-268258,250 total
    Common Stock (249 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-266376,376 total
    Common Stock (192 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2024-03-2618,75056,250 total
    Common Stock (18,750 underlying)
Footnotes (4)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
  • [F2]Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
  • [F3]The RSUs vested 25% on the one-year anniversary of the grant date and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
  • [F4]The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary